SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Casey DE, Keepers GA. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol. Ser. 1988; 5: 7493.
  • 2
    Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol. Biochem. Behav. 1994; 49: 663667.
  • 3
    Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K. Tardive dyskinesia and ethnicity: Review of the literature. Ann. Clin. Psychiatry 1997; 9: 5359.
  • 4
    Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr. Genet. 2000; 10: 911.
  • 5
    Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 10811090.
  • 6
    Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanism and tardive dyskinesia. CNS Drugs 2003; 17: 4762.
  • 7
    Fachinetto R, Villarinho JG, Wagner C et al. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: Role of dopamine transporter. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 14781486.
  • 8
    Thaakur SR, Jyothi B. Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats. J. Neural. Transm. 2007; 114: 12171225.
  • 9
    Jope RS, Roh MS. Gkycogen Synthase Kinase-3 (GSK-3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 2006; 7: 14211434.
  • 10
    Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001; 65: 391426.
  • 11
    Beasley C, Cotter D, Khan N et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci. Lett. 2001; 302: 117120.
  • 12
    Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr. Res. 2001; 52: 101105.
  • 13
    Nadri C, Dean B, Scarr E, Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr. Res. 2004; 71: 377382.
  • 14
    Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593598.
  • 15
    Lewin GR, Barde YA. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996; 19: 289317.
  • 16
    Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. Schizophr. Res. 2005; 74: 263270.
  • 17
    Foulstone EJ, Tavare JM, Gunn-Moore FJ. Sustained phosphorylation and activation of protein kinase B correlates with brain-derived neurotrophic factor and insulin stimulated survival of cerebellar granule cells. Neurosci. Lett. 1999; 264: 125128.
  • 18
    Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J. Neurochem. 2002; 82: 7583.
  • 19
    Lau KF, Miller CC, Anderton BH, Shaw PC. Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics 1999; 60: 121128.
  • 20
    Russ C, Lovestone S, Powell JF. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol. Psychiatry 2001; 6: 320324.
  • 21
    Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257269.
  • 22
    First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders, version 2.0 (SCID-I). New York State Psychiatric Institute, Biometrics Research, New York, 1996.
  • 23
    Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982; 39: 486487.
  • 24
    Nakata K, Ujike H, Sakai A et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci. Lett. 2003; 337: 1720.
  • 25
    Benedetti F, Bernasconi A, Lorenzi C et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett. 2004; 355: 3740.
  • 26
    Liou YJ, Liao DL, Chen JY et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med. 2004; 5: 243251.
  • 27
    Gratacòs M, González JR, Mercader JM, De Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: Meta-analysis of case–control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry 2007; 61: 911922.
  • 28
    Frodl T, Schüle C, Schmitt G et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch. Gen. Psychiatry 2007; 64: 410416.
  • 29
    Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005; 139B: 5153.
  • 30
    Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry 2005; 57: 533542.
  • 31
    Benedetti F, Serretti A, Pontiggia A et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci. Lett. 2005; 376: 5155.
  • 32
    Adli M, Hollinde DL, Stamm T et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol. Psychiatry 2007; 62: 12951302.
  • 33
    Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci. Lett. 2004; 368: 123126.
  • 34
    Mateo I, Infante J, Llorca J, Rodríguez E, Berciano J, Combarros O. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006; 21: 228232.
  • 35
    Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J. Neurochem. 2002; 82: 7583.